Skip Navigation
Skip to contents

CPP : Cardiovascular Prevention and Pharmacotherapy

Sumissioin : submit your manuscript
SEARCH
Search

Author index

Page Path
HOME > Browse articles > Author index
Search
Hyeon-Cheol Gwon 3 Articles
Characteristics of Patients with Vasospastic Angina in Korea: Data from a Large Cohort (VA-KOREA)
Sung Eun Kim, Sang-Ho Jo, Won-Woo Seo, Min-Ho Lee, Hyun-Jin Kim, Seong-Sik Cho, Kwan Yong Lee, Dong-Soo Kim, Tae-Hyun Yang, Sung-Ho Her, Seung Hwan Han, Byoung-Kwon Lee, Youngkeun Ahn, Seung-Woon Rha, Hyeon-Cheol Gwon, Dong-Ju Choi, Sang Hong Baek
Cardiovasc Prev Pharmacother. 2021;3(3):47-53.   Published online July 31, 2021
DOI: https://doi.org/10.36011/cpp.2021.3.e8
  • 974 View
  • 21 Download
Abstract PDF
The Variant Angina Korea (VA-KOREA) registry is a nationwide prospective multicenter registry designed to reflect the real-world clinical data of Korean patients with vasospastic angina (VSA). A total of 2,960 patients with chest pain and presumed VSA who underwent coronary angiography (CAG) and an ergonovine provocation test were enrolled. The primary endpoint composite of death from any cause, acute coronary syndrome, and newonset symptomatic arrhythmia during the 3-year follow-up was investigated for patient characteristics, laboratory findings, CAG findings, and medications. This article reviewed the current status of VSA in Korea and new findings from VA-KOREA registries to improve the treatment and prognosis of patients with VSA.
Erratum: Aspirin Has a Neutral Effect in Preventing Future Cardiovascular Events in Vasospastic Angina
Kwan Yong Lee, Dong Il Shin, Sung Ho Her, Seung Hwan Han, Youngkeun Ahn, Dong-Soo Kim, Dong-Ju Choi, Hyuck Moon Kwon, Hyeon-Cheol Gwon, Seung-Woon Rha, Sang-Ho Jo, Sung Cil Lim, Jun-Pyo Myong, Sang Hong Baek
Cardiovasc Prev Pharmacother. 2020;2(1):31.   Published online January 31, 2020
DOI: https://doi.org/10.36011/cpp.2020.2.e1
Corrects: Cardiovasc Prev Pharmacother 2019;1(1):30
  • 832 View
  • 7 Download
PDF
Aspirin Has a Neutral Effect in Preventing Future Cardiovascular Events in Vasospastic Angina
Kwan Yong Lee, Dong Il Shin, Sung Ho Her, Seung Hwan Han, Youngkeun Ahn, Dong-Soo Kim, Dong-Ju Choi, Hyuck Moon Kwon, Hyeon-Cheol Gwon, Seung-Woon Rha, Sang-Ho Jo, Sung Cil Lim, Jun-Pyo Myong, Sang Hong Baek
Cardiovasc Prev Pharmacother. 2019;1(1):30-42.   Published online July 31, 2019
DOI: https://doi.org/10.36011/cpp.2019.1.e4
Correction in: Cardiovasc Prev Pharmacother 2020;2(1):31
  • 1,755 View
  • 4 Download
  • 2 Citations
Abstract PDF
Background
The aim of this multi-center prospective registry study was to evaluate the clinical efficacy of low-dose aspirin in vasospastic angina (VA) patients for the prevention of future cardiovascular events.
Methods
A total of 1,717 patients with positive and intermediate results of an intracoronary ergonovine provocation test in the VA in Korea registry (n=2,960) were classified into 100 mg/day aspirin intake (aspirin, n=743) and no-aspirin intake (control, n=974) groups. The primary end-point was a composite of major adverse cardiac events (MACEs) including cardiac death, new-onset arrhythmia, and acute coronary syndrome.
Results
The median follow-up duration was 2.0 years (25–75th, interquartile range 0.9–3.0 years). Cumulative composite MACE in the propensity score matched-pair cohort (n=1,028) was 3.6%. There was no significant difference in composite MACE between the aspirin and control groups (3.1% vs. 4.1%; hazard ratio [HR], 1.18; 95% confidence interval [CI], 0.61–2.26; p=0.623). A sensitivity analysis of only the VA-positive population showed these results to be consistent. Even for patients with minimal organic stenosis (n=369), aspirin usage was not related to the incidence of a composite MACE (HR, 1.61; 95% CI, 0.55–4.72; p=0.380).
Conclusions
Low-dose aspirin does not protect against future cardiovascular events in VA patients, even patients who combine with minimal coronary artery stenosis.

Citations

Citations to this article as recorded by  
  • Characteristics of Patients with Vasospastic Angina in Korea: Data from a Large Cohort (VA-KOREA)
    Sung Eun Kim, Sang-Ho Jo, Won-Woo Seo, Min-Ho Lee, Hyun-Jin Kim, Seong-Sik Cho, Kwan Yong Lee, Dong-Soo Kim, Tae-Hyun Yang, Sung-Ho Her, Seung Hwan Han, Byoung-Kwon Lee, Youngkeun Ahn, Seung-Woon Rha, Hyeon-Cheol Gwon, Dong-Ju Choi, Sang Hong Baek
    Cardiovascular Prevention and Pharmacotherapy.2021; 3(3): 47.     CrossRef
  • Welcome to the New JournalCardiovascular Prevention and Pharmacotherapy
    Mi-Jeong Kim, Jang-Whan Bae, Dae Ryong Kang
    Cardiovascular Prevention and Pharmacotherapy.2019; 1(1): 1.     CrossRef

CPP : Cardiovascular Prevention and Pharmacotherapy